Form 4: IDEAYA Biosciences Director Jeffrey Stein Granted 20,000 Stock Options

Jeffrey Stein, a Director at IDEAYA Biosciences, Inc. (IDYA), was granted 20,000 stock options with an exercise price of $21.78, aligning his interests with shareholders.

Summary

• Jeffrey Stein, a Director of IDEAYA Biosciences, Inc. (IDYA), was granted 20,000 stock options on June 24, 2025.
• The stock options have an exercise price of $21.78 per share.
• The options are exercisable immediately upon grant, with an expiration date of June 24, 2035.
• The shares subject to the option will vest 100% on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the Annual Meeting following the grant date, provided Mr. Stein continues to serve on the Board through the vesting date.
• Following this transaction, Jeffrey Stein beneficially owns 20,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns management's interests with shareholders and signals confidence in the company's future, although it is a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to a director, Jeffrey Stein, aligns his financial interests directly with the long-term performance of IDEAYA Biosciences, Inc. and its shareholders.
• Equity compensation is a standard practice that can incentivize directors to contribute to the company's growth and success.

Future Outlook

The vesting schedule for the stock options indicates an expectation for Jeffrey Stein to continue his service on the Board of Directors for at least one year or until the next Annual Meeting, whichever is earlier, to fully realize the equity compensation.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages. This aligns the interests of leadership with long-term shareholder value creation, particularly in growth-oriented sectors like biotech where future potential is highly valued.

Related Party Transactions

• The grant of 20,000 stock options to Jeffrey Stein, a Director of IDEAYA Biosciences, Inc., constitutes a related party transaction as it involves equity compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive signal, aligning the director's financial incentives with shareholder value creation. It may also indicate confidence from the board in the company's future prospects.
• Employees: While not directly impacting general employees, such compensation practices for leadership can reflect the company's overall approach to incentivizing performance.

Next Steps

• The stock options will vest 100% on the earlier of the first anniversary of the grant date (June 24, 2026) or immediately prior to the Annual Meeting following the grant date, subject to continued service.

Key Dates

Keywords

IDEAYA Biosciences, IDYA, Jeffrey Stein, Stock Option, Insider Transaction, Director Compensation, Equity Grant, SEC Form 4